🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
BioInvent International AB (publ) (STO:BINV)
Sweden flag Sweden · Delayed Price · Currency is SEK
2.090
-0.080 (-3.69%)
Nov 20, 2026, 5:29 PM CET
← View all transcripts

BioStock Life Science Summit 2026

Nov 4, 2026

Summary

BI-1808 is designed to convert cold tumors into immune-infiltrated tumors and is showing early activity alone and with anti-PD-1. The priority for the coming year is testing safe addition to an approved ovarian-cancer immunotherapy regimen.

Björn Frendéus
Chief Scientific Officer, BioInvent

Now, for those of you not familiar with BioInvent, we are a Swedish biotech dedicated to the discovery and development of antibody-based drugs for immunotherapy of cancer. We have four ongoing clinical programs. They are all pretty much in phase II, and with emerging compelling signals of efficacy. We have a world-class scientific team fueled by a unique and validated discovery platform, and very importantly, internal GMP manufacturing capabilities and clinical development capabilities as well, allowing us to flexibly and based on internal priorities progress our programs. We are listed on the Stockholm Stock Exchange. Why immunotherapy? Clearly, it is not the most fashionable type of therapy today, but we are convinced, based on data, that this is really the way forward. Why do I say this?

It is because immune-activating antibodies uniquely, in an unparalleled manner, are the only class of drugs that can induce long-lasting responses and cures in a great variety of different cancers, irrespective of which tumor antigens are being expressed by individual patients and cancer cells. The powerful activity of these drugs is reflected in the survival graph, and in particular by the flattening of the survival curve. These are patients that have been treated with immune-activating checkpoint-blocking antibodies. Similar numbers and fractions of patients have survived 10 years after start of treatment compared with three years, saying that between three and 10 years, nothing much happens. Effectively, these patients have been cured. As great as these drugs are, they are only active in patients whose tumors have been infiltrated by the immune system, so-called hot tumors.

Accordingly, at the underside of that coin, those patients whose tumors are not infiltrated rarely respond to these types of drugs. If we could come up with mechanisms that allow the infiltration of the immune system into the tumor, maybe we can make these very powerful drugs work also in half of the patients that do not respond to the currently available drugs. When I say half of patients, I mean half of cancer patients, not a particular type of cancer. You can imagine the significant unmet need and the market potential of such drugs. Remarkably, this is what our lead antibody, BI-1808, which is specific for a new type of targeted immune receptor, TNFR2, seems to achieve. Preclinically, as we have exhaustively characterized and published recently, but also more importantly, translating to patients, and I will show you some of that data.

What the drug does is it does a few different things. Firstly, it binds to myeloid suppressive cells. These are cells that can make up half of the volume of a tumor, so they are very abundant in a tumor. When it binds to those cells, it activates them and transforms them to become good guy myeloid cells. These myeloid cells will then call for the CD8-positive T cells to infiltrate that cold tumor, causing inflammation, which is really what we need for the existing drugs to work. When we then combine with agents such as those targeting anti-PD-1, pembrolizumab indicated here, we can actually see preclinical synergistic effects. Time flies. In the lower two figure G here, you are looking at tissue sections of a tumor.

The good guy CD8 T cells are shown in green, and you can appreciate that there aren't many green cells here. This is entirely as expected. This is a patient that has a type of cancer that is known to be cold, gastrointestinal stromal tumor. Look then to the right, at week five, following treatment with our antibody, numerous CD8-positive T cells have infiltrated, and not only that, they have become magenta in color, meaning they are activated. So, good guy cells that have been activated and can kill off the tumor cells. Accordingly, you're seeing in figure D, in the top, these are tumor volumes as measured by radiography. All of four target lesions have very impressively regressed in response to single-agent treatment with this drug.

We then seen similar types of responses in a patient with ovarian cancer, another prototypically cold type of tumor, and additionally, in lung cancer. That's consistent with the immune-activating properties of the drug and the broad applicability across different types of solid cancer. Based on our preclinical findings that our mechanisms seem to at least combine very well, and in some cases synergistically with anti-PD-1, we have then moved forward in the clinical studies to do combination treatment, and choosing ovarian cancer as one important lead indication.

In essence, what this graph is showing you is that the mechanisms I just told you about, deleting T regulatory cells, expanding CD8-positive T cells, getting macrophages going, the myeloid cells, and then also, very interestingly, inducing the new formation of immune structures in the tumor that can be really helpful to get rid of the cancer, are happening in these patients. They're happening with our antibody alone, but most of them are then enhanced when we combine with anti-PD-1. Does it matter, or is this just sort of an academic exercise of what's going on in a patient? Well, it does seem to matter, because we're seeing compelling response rates to this combination over and above what you would see with anti-PD-1 treatment alone, which is less than one in 10 patients responding.

Currently, we've looked at some 35 patients, and approximately a quarter of those seem to be responding to this combination therapy. We see that it's not only specific to one subtype of ovarian cancer, but also other types. Clear cell and the high-grade serous adenocarcinomas are shown here. The responses are durable, meaning a patient will benefit, on average, for a long period following treatment with our antibodies. So we're not the only ones that have been interested in ovarian cancer, and I'll get back to that in a couple of minutes. One of the companies that have been interested is Merck, and they have developed their own sort of immune modulatory combination consisting of their PD-1 antibody, pembrolizumab, and a chemo immunomodulatory drug, I would call it, called paclitaxel.

If you are looking at the blue line in the left graph, you will appreciate that at the end of that curve, it seems to flatten out. You see that there is actually only a fraction of patients where this is happening, but that is then indicative of these long-term potential for curative responses happening in that arm of this trial, which is not occurring following the chemotherapy treatment alone. Again, consistent with the hypothesis that if we combine the immune-activating drugs with other drugs that have different mechanisms, we may be able to achieve these very long-lasting potential for curative effects in patients with ovarian cancer.

I do not have time to show you all of the data, but if you look in the graph to the right, that actually shows that our drug, BI-1808, combines very effectively with the two components of the approved drug, the only immunotherapy combination approved in ovarian cancer, both paclitaxel and PD-1. We, of course, ask the question, how about if we add our drug BI-1808, which, by the way, and very importantly, is super safe. We have observed no greater than adverse event grade 2 in single-agent dose escalation phases with our antibody, and we are getting pretty much a similar tolerability profile to PD-1 single-agent treatment when we add our drug on top. Safe, and you can see that purple line is really the only one in this very aggressive ovarian cancer experimental model achieves meaningful long-term survival, and again, potential for cure.

Coming back to the question of competition in cancer in general is fierce. Of course, this is true also in ovarian cancer. Besides the immunotherapy regimen, which by the way, is the one that provides the longest overall survival of all of the recently approved classes, there are drugs, antibody-drug conjugates, there are glucocorticoid receptor blockers that will be used here. It is not entirely clear how they will be used and what fraction will be used and in what order and so on and so forth. The thing I would like to point out is, our mechanism is, of course, not specific to ovarian cancer, and it is also not specific to any specific combination with anti-PD-1 alone. The ADC, for example, here has been conjugated with a toxic small molecule compound that is very similar to the one used in the approved IO regimen, paclitaxel.

It is a microtubule inhibitor. We are, of course, doing preclinical studies to assess also combinatorial activity with the ADCs. We think that there is very broad potential for our drug across many different types of solid cancers and in combination with different emerging and approved other drugs. In the coming year, the single most important milestone will be for us to demonstrate that we can safely add our drug on top of that recently approved IO regimen, and hopefully achieving something that looks at all similar to the transformatively increased activity we are seeing in the animals. With that, I will thank you, and happy to take any questions.

Operator

Thank you. We have a question there.

Björn Frendéus
Chief Scientific Officer, BioInvent

Yeah

Operator

There we have a microphone on its way.

Speaker 3

Extremely intriguing. Thank you very much. My question concerns the regulatory pathway, because what it sounds to me like is that you are developing something that is an efficacy enhancer, but not effective by itself. I am wondering how you place this in your clinical development and when you talk with regulatory authorities about that.

Björn Frendéus
Chief Scientific Officer, BioInvent

Yeah, great question. I think both from a development perspective and perhaps also for investors and partners. I will try and comment a bit on both, actually. Addressing your question, it does have single-agent activity. In fact, it has a similar response rate compared with, if you look across the types of cancers that have been studied, and of course, we have not tested all of what anti-PD-1 has been used in, similar to what you would expect from anti-PD-1 across different solid cancers. That is pretty impressive because anti-PD-1 is the, by far, to my mind, the most active and best drug that has been produced in a very long period of time. So it does have single-agent activity. The fact that it is safe allows us to add it on top of other things safely. Of course, I cannot overemphasize that.

If you have toxicity with one thing and with the other, odds are you're going to have to decrease dose, and it's not going to be effective. I think that's a bit of a win. It's more challenging that we don't have a single molecule that will cure all of cancer. That would be really handy, and I think many people are looking for this and hoping for it, but hope is not a strategy. I think, hopefully before long, people will come to the realization that with this type of mechanism, and if I have enough many horses to bet on in my race, and that requires a bigger player, this could be a really interesting complement to some of the very powerful drugs those guys have in their pipelines.

Speaker 4

Yes. I was very pleased to see that you included Corcept's relacorilant drug. You're kind of aiming at the same patient group as far as I'm seeing it. And that's already approved, 92% up from first quarter.

Björn Frendéus
Chief Scientific Officer, BioInvent

Sorry, which drug are you referring to?

Speaker 4

From Corcept.

Björn Frendéus
Chief Scientific Officer, BioInvent

From?

Speaker 4

Corcept Therapeutics.

Björn Frendéus
Chief Scientific Officer, BioInvent

Which one is this?

Speaker 4

If you go to your last slide, it is your.

Björn Frendéus
Chief Scientific Officer, BioInvent

Oh, you mean the glucocorticoid?

Speaker 4

Correct. So 1,700 patients have already been drugged with that.

Björn Frendéus
Chief Scientific Officer, BioInvent

Yes.

Speaker 4

It's had 92% increase since first quarter.

Björn Frendéus
Chief Scientific Officer, BioInvent

Yes.

Speaker 4

You want to position yourself, as I see, in that group. Just let me finish. Then you, ESMO last week, a lot of data on ovarian cancer. The one before that. Yeah, the slide before that. How do you see, because you're saying not approved yet, so Genmab's ADC

Björn Frendéus
Chief Scientific Officer, BioInvent

Yes

Speaker 4

is pretty good.

Björn Frendéus
Chief Scientific Officer, BioInvent

Yes.

Speaker 4

It beats all the existing opportunities. Can you please elaborate a little bit on your-

Björn Frendéus
Chief Scientific Officer, BioInvent

Yeah, I will start with the Genmab, which I think, you know. Can you bring up that slide or no? We do not have time maybe. Yeah, anyways, the Genmab folate receptor alpha targeting antibody has a sort of second-generation type of toxin conjugated to it compared with ELAHERE, which is the recently approved. Yeah, right.

Speaker 4

ROSELLA is Corcept.

Björn Frendéus
Chief Scientific Officer, BioInvent

Yes. Yeah, yeah. What I am saying is, the Genmab antibody is a sort of second-generation variant of this. It is not dependent on a biomarker to treat patients and that sort of thing. I think the point I am trying to make is with the ADCs, you can have smashing overall response rates, you know? Very, very powerful. But they all, before long, patients will develop a resistance, right? This is a chemotherapy. There is no magic to it. The immune modulators, they work by activating the immune system. If you can get it right, the graph I showed you can get sort of very long-term survival and potential for cure. Of course, we are not there yet.

If you look at this study, where they added the immune modulator on top of a very active component used exhaustively in ovarian cancer, actually in most of these studies, except the ADC, paclitaxel, you can get the longer-term responses. So, our bet is for something that could be used across these different combinations. Of course, we are not going to go with all. Genmab's antibody might be a smashing hit, right? Because you would get those fantastic response rates, and maybe with another time to activate the immune system, to have the protective CD8 T cells going and providing the longer-term response. That is my point.

Operator

Yes, we will take that question as well.

Speaker 5

I echo the ESMO data around ovarian cancer, but it becomes a race for durability probably. Any indications on biomarkers of patients that may predict response with the molecule?

Björn Frendéus
Chief Scientific Officer, BioInvent

Yes, so this is a very active area and focus area of ours. Of course, that would be super helpful. We all know that there really is no perfect biomarker for immunotherapy in general, and anti-PD-1 has been exhaustively used. Before getting that right, I think providing and identifying the most appropriate combination is going to be useful. Because, again, if you go back to something like the Genmab compound or the AbbVie that has been approved, you will get very high response rates to begin with. And all of those patients could be treated, potentially without the biomarker, as would be the case for the Genmab antibody. Then a greater fraction of those patients would remain in response and ultimately have a greater overall survival. So again, it is that same bet.

We may, and of course hope and expect, to increase response rates a bit, but in the end, the overall value proposition is increasing survival for these patients. It's not seeing that something happened to my tumor and then losing it too quickly.

Operator

Thank you, Björn.

Björn Frendéus
Chief Scientific Officer, BioInvent

Thank you.